A Phase 1, Randomized, 2-Way Crossover, Multiple Dose, Open Label Study Of The Effect Of CP-690,550 On Midazolam Pharmacokinetics In Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2012
At a glance
- Drugs Midazolam; Tofacitinib
- Indications Anxiety disorders; Epilepsy; Irritable bowel syndrome; Rheumatoid arthritis; Transplant rejection
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Aug 2009 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 14 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jul 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.